The World Health Organization is discontinuing the WHO’s trials of the malaria drug hydroxychloroquine and the combination HIV drug lopinavir/ritonavir in hospitalized patients with COVID-19 after they failed to reduce mortality.
COVID-19 vaccine candidates will enter late-stage clinical studies by the end of the month, with others beginning in August, September and October, the U.S. government’s top infectious diseases expert said.
Regeneron Pharmaceuticals and Sanofi said their rheumatoid arthritis drug Kevzara failed to meet the main goals of a U.S. study testing the medicine in the most critically ill COVID-19 patients.
The U.S. Food and Drug Administration approved ViiV Healthcare’s Rukobia (fostemsavir) as a first-in-class treatment for HIV in adults with few treatment options available.
Helsinn Group, based in Lugano, Switzerland, and MEI Pharma, with headquarters in San Diego, announced they were discontinuing their Phase III trial of pracinostat with azacytidine in acute myeloid leukemia (AML).
Tesla, the electric car company founded and run by Elon Musk, is building mobile molecular printers to assist Germany’s CureVac in manufacturing an experimental COVID-19 vaccine.
U.S. National Institutes of Health Director Dr. Francis Collins said he was optimistic that the Trump administration’s vaccine-acceleration program “Operation Warp Speed” will generate a safe and effective vaccine for COVID-19 by year end.
South San Francisco-based Akero Therapeutics presented results from a 16-week analysis of secondary and exploratory endpoints in the company’s Phase IIa BALANCED clinical trial of efruxifermin in nonalcoholic steatohepatitis (NASH).
New York-based Pfizer and Germany-based BioNTech announced preliminary data from the most advanced of four vaccine candidates against SARS-CoV-2, the virus causing COVID-19.
London-based Freeline announced the closing of a $120 million extended Series C financing to advance the company’s gene therapy programs, and is considering additional capital fundraising options during 2020.
